X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mln0128 (23) 23
index medicus (17) 17
humans (15) 15
cancer (13) 13
mtor (13) 13
tor serine-threonine kinases - antagonists & inhibitors (13) 13
oncology (12) 12
antitumor-activity (10) 10
benzoxazoles - pharmacology (10) 10
pyrimidines - pharmacology (10) 10
animals (9) 9
rapamycin (9) 9
tor protein (8) 8
cell proliferation - drug effects (7) 7
female (7) 7
mice (7) 7
activation (6) 6
apoptosis - drug effects (6) 6
article (6) 6
cell line, tumor (6) 6
cell proliferation (6) 6
growth (6) 6
mammalian target (6) 6
medicine & public health (6) 6
phosphorylation (6) 6
protein kinase inhibitors - pharmacology (6) 6
tor serine-threonine kinases - metabolism (6) 6
akt (5) 5
akt protein (5) 5
apoptosis (5) 5
cell lines (5) 5
everolimus (5) 5
ink128 (5) 5
mechanistic target of rapamycin complex 1 (5) 5
signal transduction (5) 5
therapy (5) 5
tumors (5) 5
disease models, animal (4) 4
expression (4) 4
inhibitors (4) 4
mechanistic target of rapamycin complex 2 (4) 4
multiprotein complexes - antagonists & inhibitors (4) 4
multiprotein complexes - metabolism (4) 4
pathway (4) 4
patients (4) 4
sapanisertib (4) 4
treatment outcome (4) 4
anticancer properties (3) 3
antineoplastic agents - therapeutic use (3) 3
benzoxazoles - administration & dosage (3) 3
breast cancer (3) 3
care and treatment (3) 3
cell biology (3) 3
cell growth (3) 3
combination (3) 3
in-vivo (3) 3
inhibitory concentration 50 (3) 3
intrahepatic cholangiocarcinoma (3) 3
male (3) 3
mice, inbred nod (3) 3
mice, scid (3) 3
pharmacology & pharmacy (3) 3
phase-i (3) 3
phosphorylation - drug effects (3) 3
proto-oncogene proteins c-akt - metabolism (3) 3
pyrimidines - administration & dosage (3) 3
renal-cell carcinoma (3) 3
research paper (3) 3
signal transduction - drug effects (3) 3
sirolimus - pharmacology (3) 3
torc1/2 inhibitor (3) 3
xenograft model antitumor assays (3) 3
adult (2) 2
aged (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antitumor activity (2) 2
benzoxazoles - adverse effects (2) 2
benzoxazoles - pharmacokinetics (2) 2
benzoxazoles - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
biomarkers (2) 2
blotting, western (2) 2
breast neoplasms - metabolism (2) 2
carcinoma, merkel cell - metabolism (2) 2
cell cycle (2) 2
cells (2) 2
cellular signal transduction (2) 2
cholangiocarcinoma (2) 2
cyclin-dependent kinase 4 (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
drug synergism (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
dual mtor inhibitor (2) 2
dual torc1/2 inhibitor (2) 2
erbb-2 protein (2) 2
estrogen (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 40, pp. 26032 - 26045
The mTOR pathway is activated in about 50% of patients with hepatocellular carcinoma (HCC). In an effort to identify new pathways and compounds to treat... 
Pharmacokinetics | Sapanisertib | MLN0128 | TAK228
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 6, pp. 1889 - 1900
Purpose: Over 95% of human anal cancers are etiologically associated with high-risk HPVs, with HPV type 16 (HPV16) the genotype most commonly found. Activating... 
HEAD | MUTAGENESIS | ONCOLOGY | RAS | TORC1/2 INHIBITOR | MLN0128 | PAPILLOMAVIRUS TYPE-16 E7 | ANTITUMOR-ACTIVITY | CANCER | MTOR
Journal Article
Cancers, ISSN 2072-6694, 07/2019, Volume 11, Issue 7, p. 930
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce... 
PD901 | cell proliferation | MLN0128 | apoptosis | MEK inhibitor | hepatocellular carcinoma | pan-mTOR inhibitor
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2013, Volume 110, Issue 29, pp. 11988 - 11993
Journal Article
mBio, ISSN 2161-2129, 01/2019, Volume 10, Issue 1, p. e02871-18
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2019, Volume 17, Issue 1, pp. 169 - 182
Essentials Tissue factor (TF) isoforms are expressed in pancreatic neuroendocrine tumors (pNET). TF knockdown inhibits proliferation of human pNET cells in... 
carcinoma, neuroendocrine | 0128 | protein, human | tissue factor | pancreatic neoplasms | mTOR | MLN | mTOR protein, human | MLN0128 | NF-Y | RAPAMYCIN | CELLS | ACTIVATION | COMPLEX | THROMBOSIS | CANCER GROWTH | PATHWAY | COAGULATION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | PROGRESSION | Adenocarcinoma | TOR protein | Alternative splicing | Transfection | Tissue factor | Cell lines | Isoforms | mRNA | Pancreas | Gene expression | Neuroendocrine tumors
Journal Article
Leukemia, ISSN 0887-6924, 03/2013, Volume 27, Issue 3, pp. 586 - 594
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2019, Volume 174, Issue 3, pp. 615 - 625
Journal Article
Journal of Hepatology, ISSN 0168-8278, 12/2017, Volume 67, Issue 6, pp. 1194 - 1203
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2015, Volume 14, Issue 2, pp. 395 - 406
The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular... 
MAMMALIAN TARGET | SYNOVIAL SARCOMA | MESSENGER-RNA TRANSLATION | ACTIVATION | ONCOLOGY | AKT/MAMMALIAN TARGET | EMBRYONAL RHABDOMYOSARCOMA | CELL-CYCLE | COMPLEX 2 | RAPAMYCIN PATHWAY | P70 S6 KINASE | Osteosarcoma - drug therapy | Benzoxazoles - pharmacology | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Mechanistic Target of Rapamycin Complex 2 | Pyrimidines - chemistry | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Adenosine Triphosphate - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiprotein Complexes - metabolism | Protein Kinase Inhibitors - chemistry | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Disease Models, Animal | Benzoxazoles - therapeutic use | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Down-Regulation - drug effects | Sarcoma - drug therapy | Sirolimus - pharmacology | Xenograft Model Antitumor Assays | Animals | Benzoxazoles - chemistry | Substrate Specificity - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Index Medicus | mTOR | Rapamycin | MLN0128
Journal Article
Cell Death and Disease, ISSN 2041-4889, 02/2019, Volume 10, Issue 2, pp. 120 - 12
PD901, a MEK inhibitor, has been demonstrated of therapeutic efficacy against cholangiocarcinoma (CCA) harboring K-Ras oncogenic mutations. However, most CCA... 
INTRAHEPATIC CHOLANGIOCARCINOMA | ACTIVATION | THERAPY | CLINICAL DEVELOPMENT | GROWTH | MLN0128 | STROMA | HYPOXIA | EXPRESSION | MTOR | CELL BIOLOGY | TOR protein | Cell proliferation | MEK inhibitors | Extracellular signal-regulated kinase | AKT protein | Kinases | K-Ras protein | Cell growth | Cell lines | Cell cycle | Fibroblasts | Hypoxia | Mutation | Cholangiocarcinoma | Cancer
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 400, pp. 110 - 116
Abstract Diffuse intrinsic pontine glioma (DIPG) is an invasive and treatment-refractory pediatric brain tumor. Primary DIPG tumors harbor a number of... 
Hematology, Oncology and Palliative Medicine | mTOR | Pediatric brain tumor | Sapanisertib | INK128 | MLN0128 | ACTIVATION | GRADE GLIOMA | ANTITUMOR-ACTIVITY | BREAST-CANCER CELLS | NEURAL STEM-CELLS | GLIOBLASTOMA | ONCOLOGY | K27M MUTATION | IN-VIVO | GROWTH | THERAPEUTIC TARGETS | Benzoxazoles - pharmacology | Phosphorylation | Ribosomal Protein S6 Kinases - metabolism | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Apoptosis - radiation effects | Brain Stem Neoplasms - pathology | Humans | Mechanistic Target of Rapamycin Complex 2 | Chemoradiotherapy | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiprotein Complexes - metabolism | Time Factors | Glioma - pathology | Glioma - therapy | Signal Transduction - radiation effects | Proto-Oncogene Proteins c-akt - metabolism | Brain Stem Neoplasms - enzymology | Glioma - enzymology | Neoplasm Invasiveness | Radiation-Sensitizing Agents - pharmacology | Pyrimidines - pharmacology | Mice, SCID | Cell Movement - radiation effects | Radiation Tolerance - drug effects | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Signal Transduction - drug effects | Brain Stem Neoplasms - therapy | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Cell Proliferation - radiation effects | Physiological aspects | Medical colleges | Gliomas | Analysis | Brain tumors | TOR protein | Cell proliferation | Brain | Cell survival | Inhibitor drugs | Brain cancer | Radiation | AKT protein | Pharmacology | Rapamycin | Tumorigenicity | Metabolism | Kinases | Survival | Cell growth | Inhibitors | Radiosensitization | Glioma | Mutation | Inhibition | Tumors | Apoptosis | Index Medicus | sapanisertib | pediatric brain tumor
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2014, Volume 144, Issue 2, pp. 287 - 298
Journal Article